ARTICLE | Company News
FDA approves abuse-deterrent labeling for Embeda
October 18, 2014 2:34 AM UTC
FDA approved expanded labeling for Embeda morphine sulfate/ naltrexone hydrochloride extended-release capsules from Pfizer Inc. (NYSE:PFE) to include data from abuse-deterrent studies.
Embeda is indicated to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ...